BiotechTube

Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Insomnia

Conditions

Insomnia

Trial Timeline

May 31, 2016 → Jan 30, 2018

NCT ID
NCT02783729

About Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placebo

Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placebo is a phase 3 stage product being developed by Eisai for Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT02783729. Target conditions include Insomnia.

What happened to similar drugs?

20 of 20 similar drugs in Insomnia were approved

Approved (20) Terminated (2) Active (0)
✅Zolpidem (Myslee®) + placeboAstellas PharmaApproved
✅zolpidemAstellas PharmaApproved
✅Mirtazapine TabletsSun PharmaceuticalApproved
✅Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)EisaiApproved
✅Eszopiclone + Placebo + EscitalopramSumitomo PharmaApproved
✅eszopicloneSumitomo PharmaApproved
✅Eszopiclone (Lunesta)Sumitomo PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02783729Phase 3Completed

Competing Products

20 competing products in Insomnia

See all competitors
ProductCompanyStageHype Score
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2IdorsiaPhase 2
29
Zolpidem (Myslee®) + placeboAstellas PharmaApproved
43
zolpidemAstellas PharmaApproved
43
Mirtazapine TabletsSun PharmaceuticalApproved
43
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)EisaiApproved
43
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched PlaceboEisaiPhase 1
29
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mgEisaiPhase 1
29
E2006EisaiPhase 1
29
LEM 5 mg + LEM 10 mgEisaiPhase 3
40
EszopicloneEisaiPre-clinical
26
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mgEisaiPhase 2/3
38
lemborexant + PlaceboEisaiPhase 3
40
E2006 + PlaceboEisaiPhase 2
35
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexantEisaiPhase 1
29
EszopicloneEisaiPre-clinical
26
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderlyEisaiPhase 3
40
Eszopiclone 3 mg + Eszopiclone 1 mgEisaiPhase 1
29
LY2624803Eli LillyPhase 1
29
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - TabletsEli LillyPhase 1
29
LY2624803Eli LillyPhase 1
21